Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

NCT04265274 is registered in ClinicalTrials.gov with National Cancer Institute, Slovakia as lead sponsor.

NCT NCT04265274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04265274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.
Lead sponsor
National Cancer Institute, Slovakia
Phase
Phase 2
Overall status
Withdrawn
Start date
January 1, 2020
Completion date
January 1, 2023
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer